Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension

Hypertension

Volumn 25, Issue 1, 1995, Pages 22-29

  Van Den Meiracker, Anton H ^a   Admiraal, Peter J J ^a   Janssen, Joop A ^a   Kroodsma, Jan Maarten ^b   De Ronde, Wijnand A M ^b   Boomsma, Frans ^a   Sissmann, Joëlle ^c   Blankestijn, P J ^d   Mulder, Paul G M ^e   Man In 't Veld, Arie J ^a   Schalekamp, Maarten A D H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b U Gene Research BV   (Netherlands)

^c SANOFI   (France)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

aldosterone; angiotensin I; angiotensin II; hemodynamics; hypertension, essential; norepinephrine; receptors, angiotensin; renin; uric acid

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; NORADRENALIN; PRORENIN; RECEPTOR BLOCKING AGENT; RENIN; SODIUM; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0028963378     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.25.1.22     Document Type: Article

References (27)

1. Nelson E, Merrill D, Sweet C, Badstreet D, Panebianco D, Byny R, Herman T, Lasseter K, Levy B, Lewis G, et al. Efficacy and safety of oral MK-954 (Dup 753), an angiotensin II receptor antagonist in essential hypertension. J Hypertens. 1991;9(suppl 6):s468-s469. Abstract.
2. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM. Oral administration of Dup 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of the response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
3. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
4. Tsunoda K, Abe K, Hagino T, Omat K, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a non-peptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
5. Wexler RR, Carin DJ, Duncia JV, Johnson AL, Wells GJ, Chiu AT, Wong PC, Timmermans PBMWM. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens. 1992;5:209S-220S.
6. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
7. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens. 1994;12(suppl 3):508. Abstract.
8. Derkx FHM, Tan-Tjiong H, Wenting GJ, Boomsma F, Schalekamp MADH. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension. 1983;5:244-256.
9. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44-55.
10. Véniant M, Clozel JP, Hess P, Fischli W. Effects of renin-angiotensin system blockade in guinea pigs. Hypertension. 1992;19:225-262.
11. van der Hoorn FAJ, Boomsma F, Man in 't Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 1989;487:17-27.
12. Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1981;31:81-227.
13. Johns DW, Peach MJ, Gomez RA, Inagami T, Carey RM. Angioteasin II regulates renin gene expression. Am J Physiol. 1990;259:F882-F887.
14. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Timmermans PBMWM. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension. 1990;15:459-468.
15. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists: antihypertensive activity of Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:726-732.
16. Abdelrahman AM, Burrell LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens. 1993;11(suppl 3):S23-S26.
17. Wong PC, Price WA, Chiu AT, Carini DJ, Duncia JV, Johnson AL, Wexler RR, Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension. 1990;15:823-834.
18. Tofovi S, Pang A, Jackson EK. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension. 1991;18:774-782.
19. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tufft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN. Antihypertensive effect of oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978;298:991-995.
20. Mancia G, Parati G, Pomidossi G, Grassi G, Bertinieri G, Buccino N, Ferrari A, Gregorini L, Rupoli L, Zanchetti A. Modification of arterial baroreflexes by captopril in essential hypertension. Am J Cardiol. 1982;49:1415-1419.
21. Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979;1:39-46.
22. Nicholls MG, Espiner EA, Miles KD, Zweifler AJ, Julius S. Evidence against an interaction of angiotensin II with the sympathetic nervous system in man. Clin Endocrinol. 1981;15:423-430.
23. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of Dup 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333-335.
24. Burnier M, Hagmann M, Declacretaz E, Brouard R, Armagnac C, Nussberger J, Waeber B, Brunner HR. The angiotensin II antagonist SR 47436 (BMS 186295) increases dose-dependently urinary sodium excretion but not uric acid in healthy normotensive volunteers. J Hypertens. 1994;12(suppl 3):s98. Abstract.
25. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.
26. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hyperteasion. Kidney Int. 1981;20:240-245.
27. Weber A. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens. 1992;5(suppl):247S-251S.